Andrea Hagemann
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
pERK and other potential biomarkers of therapy response in LGSOC. A, pERK IHC examples demonstrating negative (0), weak (1+), moderate (2+), and intense (3+) positivity for histoscore calculation. Scale bars, 50 µm. B, Response to trametinib (top) and physician’s choice SOC (bottom) according to KRAS / BRAF / NRAS mutation status (left), pERK status (middle), and chr1 abnormalities (right). C, pERK histoscore according to KRAS / BRAF / NRAS mutation type. Labels specify the numbers within each group that were evaluable for pERK expression levels. D, pERK histoscore by chr1p-loss status. E, Frequency of pERK status between chr1p-loss and -intact groups. Chr1pq-aberrant, chr1p-loss with concurrent chr1q-gain.
Year:
2026
Study case flow diagram for WES of translational specimens from patients enrolled in GOG281. One hundred thirty-four samples underwent successful WES, of which 112 were also evaluable for pERK via IHC. Additionally, 36 samples were evaluable for pERK IHC that did not have matching WES.
Year:
2026
Molecular landscape of tumor samples from patients enrolled in GOG281/LOGS. MAPK-associated, MAPK-associated genes as defined in the Gene Ontology Term GO:0000165; Chr1pq-aberrant, chr1p-loss with concurrent chr1q-gain.
Year:
2026
Impact of pERK status and KRAS / BRAF / NRAS mutation status on GOG281 patient outcome. A, PFS of GOG281/LOGS patients with low-pERK tumors (pERK ≤ 140) in trametinib versus SOC arms. B, PFS of GOG281/LOGS patients with high-pERK tumors (pERK > 140) in trametinib versus SOC arms. C , PFS of GOG281/LOGS patients with KRAS / BRAF / NRAS WT tumors in trametinib versus SOC arms. D , PFS of GOG281/LOGS patients with KRAS / BRAF / NRAS -mutant tumors in trametinib versus SOC arms. Labeled HR refer to comparison of trametinib versus SOC arm.
Year:
2026
Purpose: Low-grade serous ovarian carcinoma (LGSOC) is a distinct form of ovarian cancer characterized by younger patient age and relative chemoresistance. The GOG281/LOGS trial (NCT02101788) investigated the efficacy of the MEK inhibitor trametinib compared with physician’s choice standard-of-care (SOC) in patients with LGSOC with persistent/recurrent disease. The study demonstrated significantly improved progression-free survival (PFS) in the trametinib-treated arm. Experimental Design: Two hundred and sixty patients with recurrent/persistent LGSOC were enrolled and randomly assigned in GOG281. We performed molecular analysis of 170 patients with available tumor specimens, comprising whole-exome sequencing and phospho-ERK (pERK) IHC, to identify biomarkers of clinical benefit from trametinib. The demographics of the translational cohort ( n = 170) were comparable with those of the total trial cohort. Results: High tumor pERK expression (greater than the median histoscore of 140) was associated with significantly prolonged PFS with trametinib treatment versus SOC (median 20.1 vs. 5.6 months, log-rank P P = 0.023). Tumors harboring canonical RAS–RAF–MAPK mutations ( KRAS/BRAF/NRAS : 44/134, 32.8% of cases) had a higher response rate to trametinib (50.0% vs. 8.3%; Barnard’s P = 0.0004; test for interaction P = 0.054), but KRAS / BRAF / NRAS status was not predictive of prolonged PFS (test for interaction P = 0.719). KRAS amplification ( n = 5 without KRAS / NRAS / BRAF mutation) and mutation of MAPK-associated genes ( n = 25 without KRAS / NRAS / BRAF mutation or KRAS copy number gain) expanded the number of cases with identifiable MAPK defects to 55.2%, but consideration of these events did not improve the discrimination of trametinib responders. Chr1p loss (49% of cases) was associated with lower pERK expression ( P = 0.021). Conclusions: This exploratory analysis suggests that pERK expression and mutation of KRAS / BRAF / NRAS are candidate biomarkers of improved PFS and response to trametinib, respectively.
Year:
2026
BRCA -mutated ovarian cancer commonly develops resistance to poly (ADP-ribose) polymerase (PARP) inhibitors. Here, we investigated the DNA repair protein RAD52 as a potential target to overcome resistance. In analysis of The Cancer Genome Atlas datasets and immunohistochemistry of tissue microarrays, elevated RAD52 expression correlated with poor overall survival in patients with high-grade serous ovarian cancers. We tested two PARP inhibitor-resistant Brca2 -deficient mouse ovarian cancer models, ID8-OR and HGS2-OR. HGS2- OR cells had higher RAD52 expression than parental lines. Rad52 knockout or knockdown restored PARP inhibitor sensitivity in both models. In syngeneic mice, ID8-OR cells in which Rad52 was knocked out yielded lower tumor burden and longer overall survival than control cells. Rad52 depletion impaired single-strand annealing and homologous recombination and led to accumulation of DNA double-strand breaks after PARP inhibitor treatment. RNA sequencing demonstrated that PARP inhibitor treatment induced Polq expression in Brca2 - and Rad52 -deficient cells, suggesting a switch to microhomology-mediated end joining. Finally, the RAD52 inhibitor D-I03 synergized with a PARP inhibitor to reduce cell viability and tumor burden and prolong survival. Collectively, our findings establish RAD52 as a promising therapeutic target to overcome PARP inhibitor resistance in BRCA2 -mutated ovarian cancer and offer mechanistic insights to inform future clinical strategies.
Year:
2025
High-grade serous ovarian cancer (HGSC) accounts for more than 200,000 deaths each year. Despite recent advances in treating HGSC with neoadjuvant chemotherapy, the majority of patients ultimately develop chemotherapy resistance. HGSC is characterized by TP53 mutations and widespread copy-number alterations and occurs frequently in the setting of deleterious germline BRCA1/2 variations, but many cases lack putative driver mutations. In this study, we performed whole-exome, whole-genome, and whole-transcriptome sequencing along with mass spectrometry to characterize the molecular landscape of HGSC in 22 paired samples obtained before and after neoadjuvant chemotherapy. Responsiveness to chemotherapy was determined for each patient. Evidence at the DNA, RNA, and protein level revealed numerous defects in cell–cell and cell–matrix interactions, as well as disruption of cell polarity and cytoskeletal regulation in HGSC, indicating that defects in epithelial integrity were present in the majority of patients with HGSC. Nonresponsive HGSC harbored subclones with putative survival mutations. Additionally, ineffective nonsense-mediated decay resulted in the persistence of transcripts with frameshift mutations that were translated into aberrant proteins detectable in HGSC samples. Together, these findings suggest that HGSC may arise through defects in the maintenance of epithelial integrity that lead to the shedding of malignant cells throughout the peritoneum, and the presence of resistant subclones prior to chemotherapy may decrease the chemosensitivity of patients. Significance: Comprehensive longitudinal characterization of ovarian cancer identifies pathways that promote tumorigenesis and provides insights into regulators of chemotherapy response, which could help develop strategies to improve outcomes for patients.
Year:
2025
Purpose: To determine the ability of RAD51 foci to predict platinum chemotherapy response in high-grade serous ovarian cancer (HGSOC) patient-derived samples. Experimental Design: RAD51 and γH2AX nuclear foci were evaluated by immunofluorescence in HGSOC patient-derived cell lines ( n = 5), organoids ( n = 11), and formalin-fixed, paraffin-embedded tumor samples (discovery n = 31, validation n = 148). Samples were defined as RAD51-High if >10% of geminin-positive cells had ≥5 RAD51 foci. Associations between RAD51 scores, platinum chemotherapy response, and survival were evaluated. Results: RAD51 scores correlated with in vitro response to platinum chemotherapy in established and primary ovarian cancer cell lines (Pearson r = 0.96, P = 0.01). Organoids from platinum-nonresponsive tumors had significantly higher RAD51 scores than those from platinum-responsive tumors ( P P P = 0.05). The RAD51 score was predictive of chemotherapy response score [AUC, 0.90; 95% confidence interval (CI), 0.78–1.0; P P P P = 0.003) than RAD51-High status. Conclusions: RAD51 foci are a robust marker of platinum chemotherapy response and survival in ovarian cancer. The utility of RAD51 foci as a predictive biomarker for HGSOC should be tested in clinical trials.
Year:
2025
Ovarian cancer is the leading cause of gynecological cancer-related deaths. The propensity for metastasis within the peritoneal cavity is a driving factor for the poor outcomes associated with this disease, but there is currently no effective therapy targeting metastasis. In this study we investigate the contribution of stromal cells to ovarian cancer metastasis and identify normal stromal cell expression of the collagen receptor, Discoidin Domain Receptor 2 (DDR2), that acts to facilitate ovarian cancer metastasis. In vivo, global genetic inactivation of Ddr2 impairs the ability of Ddr2-expressing syngeneic ovarian cancer cells to spread throughout the peritoneal cavity. Specifically, DDR2 expression in mesothelial cells lining the peritoneal cavity facilitates tumor cell attachment and clearance. Subsequently, omentum fibroblast expression of DDR2 promotes tumor cell invasion. Mechanistically, we find DDR2-expressing fibroblasts are more energetically active, such that DDR2 regulates glycolysis through AKT/SNAI1 leading to suppressed fructose-1,6-bisphosphatase and increased hexokinase activity, a key glycolytic enzyme. Upon inhibition of DDR2 we find decreased protein synthesis and secretion. Consequently, when DDR2 is inhibited, there is reduction in secreted extracellular matrix proteins important for metastasis. Specifically, we find that fibroblast DDR2 inhibition leads to decreased secretion of the collagen crosslinker, LOXL2. Adding back LOXL2 to DDR2 deficient fibroblasts rescues the ability of tumor cells to invade. Overall, our results suggest that stromal cell expression of DDR2 is an important mediator of ovarian cancer metastasis. Implications: DDR2 is highly expressed by stromal cells in ovarian cancer that can mediate metastasis and is a potential therapeutic target in ovarian cancer.
Year:
2024
Purpose: To determine the ability of RAD51 foci to predict platinum chemotherapy response in high-grade serous ovarian cancer (HGSOC) patient-derived samples. Experimental Design: RAD51 and γH2AX nuclear foci were evaluated by immunofluorescence in HGSOC patient-derived cell lines ( n =5), organoids ( n =11), and formalin-fixed, paraffin-embedded tumor samples (discovery n =31, validation n= 148 ) . Samples were defined as RAD51-High if >10% of geminin-positive cells had ≥5 RAD51 foci. Associations between RAD51 scores, platinum chemotherapy response, and survival were evaluated. Results: RAD51 scores correlated with in vitro response to platinum chemotherapy in established and primary ovarian cancer cell lines (Pearson r=0.96, P =0.01). Organoids from platinum-nonresponsive tumors had significantly higher RAD51 scores than those from platinum-responsive tumors ( P P P = 0.05). The RAD51 score was predictive of chemotherapy response score (AUC 0.90, 95% CI 0.78-1.0; P P P P= 0.003) than RAD51-High status. Conclusions: RAD51 foci are a robust marker of platinum chemotherapy response and survival in ovarian cancer. The utility of RAD51 foci as a predictive biomarker for HGSOC should be tested in clinical trials.
Year:
2024
Year:
2024
Collaborators (33)
Charlie Gourley
University of Edinburgh
Kevin Cho
Washington University in St. Louis
Mary M. Mullen
Washington University
Mitchell Edelson
Thomas Jefferson University
Austin Miller
Asst Professor of Oncology, Biostatistics and Bioinformatics
Roswell Park Comprehensive Cancer Center
Benjamin Bitler
Professor
University of Colorado Anschutz Medical Campus
Whitney Grither
Washington University
Katherine C. Fuh
Washington University
Dineo Khabele
Professor and Chair
Washington University in St. Louis
Anil Sood
Professor
The University of Texas MD Anderson Cancer Center
C Simon Herrington
Professor
University of Edinburgh
David Gershenson
Professor
The University of Texas MD Anderson Cancer Center
Oliver Dorigo
Stanford University School of Medicine
Robert L Hollis
Group Leader, CRUK Career Development Fellow
University of Edinburgh
Vijayalaxmi Gupta
Senior Scientist
Washington University in St. Louis
Mathew A. Powell
Professor
Washington University in St. Louis
Ian Hagemann
Professor
Washington University in Saint Louis School of Medicine
Alex Holehouse
Associate Professor
Washington University in Saint Louis School of Medicine
Robi Mitra
Professor
Washington University in St. Louis
Ailith Ewing
University of Edinburgh
Lulu Sun
Washington University
Nima Mosammaparast
Washington University in St. Louis
Gary J. Patti
Washington University in St. Louis
Susana Banerjee
Professor in Women's Cancers (Systemic Therapy and Clinical Trials)
Institute of Cancer Research
Shariska Harrington
Assistant Professor
Mayo Clinic
rebecca arend
Medical Director of the Clinical Trials Office
The University of Alabama
William Rodgers
Professor
Weill Cornell Medicine
Gregory Longmore
Professor
Washington University in St. Louis
Lindsay Kuroki
Assistant Professor
Washington University School of Medicine
Violeta Serra
Group Leader
Vall d'Hebron Institute of Oncology
Kwong-Kwok Wong
Professor
The University of Texas MD Anderson Cancer Center
Robert L. Coleman
-
Stephanie Gaillard
Johns Hopkins University
Make your next move.
Prepare your application
Review drafts before you send them.